172 related articles for article (PubMed ID: 15548704)
1. Interferon gamma enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma.
Merchant MS; Yang X; Melchionda F; Romero M; Klein R; Thiele CJ; Tsokos M; Kontny HU; Mackall CL
Cancer Res; 2004 Nov; 64(22):8349-56. PubMed ID: 15548704
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis.
Kontny HU; Hämmerle K; Klein R; Shayan P; Mackall CL; Niemeyer CM
Cell Death Differ; 2001 May; 8(5):506-14. PubMed ID: 11423911
[TBL] [Abstract][Full Text] [Related]
3. Platelet-derived growth factor receptor beta inhibition increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity: imatinib and TRAIL dual therapy.
Wang Y; Mandal D; Wang S; Kleinerman ES; Pollock RE; Lev D; Hayes-Jordan A
Cancer; 2010 Aug; 116(16):3892-902. PubMed ID: 20564078
[TBL] [Abstract][Full Text] [Related]
4. Type I interferon and TNFalpha cooperate with type II interferon for TRAIL induction and triggering of apoptosis in SK-N-MC EWING tumor cells.
Abadie A; Besançon F; Wietzerbin J
Oncogene; 2004 Jun; 23(28):4911-20. PubMed ID: 15077162
[TBL] [Abstract][Full Text] [Related]
5. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC
Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300
[TBL] [Abstract][Full Text] [Related]
6. Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma.
Sturla LM; Westwood G; Selby PJ; Lewis IJ; Burchill SA
Cancer Res; 2000 Nov; 60(21):6160-70. PubMed ID: 11085540
[TBL] [Abstract][Full Text] [Related]
7. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model.
Zhang L; Zhang X; Barrisford GW; Olumi AF
Cancer Lett; 2007 Jun; 251(1):146-57. PubMed ID: 17184908
[TBL] [Abstract][Full Text] [Related]
8. [Role of caspase-8 and DR5 in TRAIL-induced apoptosis of neuroblastoma cells].
Tong HX; Zhang JH; Ma L; Lu CW; Zhang JH
Zhongguo Dang Dai Er Ke Za Zhi; 2006 Aug; 8(4):327-30. PubMed ID: 16923369
[TBL] [Abstract][Full Text] [Related]
9. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2.
Motoki K; Mori E; Matsumoto A; Thomas M; Tomura T; Humphreys R; Albert V; Muto M; Yoshida H; Aoki M; Tamada T; Kuroki R; Yoshida H; Ishida I; Ware CF; Kataoka S
Clin Cancer Res; 2005 Apr; 11(8):3126-35. PubMed ID: 15837769
[TBL] [Abstract][Full Text] [Related]
10. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y; Harada K; Ferdous T; Yoshida H
Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
[TBL] [Abstract][Full Text] [Related]
11. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
Georgakis GV; Li Y; Humphreys R; Andreeff M; O'Brien S; Younes M; Carbone A; Albert V; Younes A
Br J Haematol; 2005 Aug; 130(4):501-10. PubMed ID: 16098063
[TBL] [Abstract][Full Text] [Related]
12. Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function.
Li Y; Wang H; Wang Z; Makhija S; Buchsbaum D; LoBuglio A; Kimberly R; Zhou T
Cancer Res; 2006 Sep; 66(17):8520-8. PubMed ID: 16951164
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity of Tumor necrosis factor related apoptosis-inducing ligand towards Ewing's sarcoma cell lines.
Kumar A; Jasmin A; Eby MT; Chaudhary PM
Oncogene; 2001 Feb; 20(8):1010-4. PubMed ID: 11314037
[TBL] [Abstract][Full Text] [Related]
14. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin modulates telomerase activity in Ewing's sarcoma in vitro and in vivo.
Lanvers-Kaminsky C; Winter B; Koling S; Frodermann B; Braun Y; Schaefer KL; Diallo R; Koenemann S; Wai D; Willich N; Poremba C; Schuck A
Oncol Rep; 2005 Sep; 14(3):751-8. PubMed ID: 16077987
[TBL] [Abstract][Full Text] [Related]
16. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
17. IFNgamma sensitization to TRAIL-induced apoptosis in human thyroid carcinoma cells by upregulating Bak expression.
Wang SH; Mezosi E; Wolf JM; Cao Z; Utsugi S; Gauger PG; Doherty GM; Baker JR
Oncogene; 2004 Jan; 23(4):928-35. PubMed ID: 14647456
[TBL] [Abstract][Full Text] [Related]
18. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
Yamamoto T; Nagano H; Sakon M; Wada H; Eguchi H; Kondo M; Damdinsuren B; Ota H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Dono K; Umeshita K; Nakamori S; Yagita H; Monden M
Clin Cancer Res; 2004 Dec; 10(23):7884-95. PubMed ID: 15585621
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
Picarda G; Lamoureux F; Geffroy L; Delepine P; Montier T; Laud K; Tirode F; Delattre O; Heymann D; Rédini F
Clin Cancer Res; 2010 Apr; 16(8):2363-74. PubMed ID: 20371692
[TBL] [Abstract][Full Text] [Related]
20. TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8.
Belyanskaya LL; Ziogas A; Hopkins-Donaldson S; Kurtz S; Simon HU; Stahel R; Zangemeister-Wittke U
Lung Cancer; 2008 Jun; 60(3):355-65. PubMed ID: 18093694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
